Topiramate in opiate withdrawal- comparison with clonidine and with carbamazepine/mianserin

Détails

ID Serval
serval:BIB_F26D25AF432A
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Topiramate in opiate withdrawal- comparison with clonidine and with carbamazepine/mianserin
Périodique
Substance Abuse
Auteur(s)
Zullino DF, Krenz S, Zimmermann G, Miozzari A, Rajeswaran RA, Kolly S, Khazaal Y
ISSN
0889-7077
Statut éditorial
Publié
Date de publication
2005
Peer-reviewed
Oui
Volume
25
Numéro
4
Pages
27-33
Langue
anglais
Notes
SAPHIRID:61689
Résumé
There are some rationales for developing anticonvulsants for the treatment of substance abuse. The blockade of the AMPA/kainate subtype of glutamate receptor by topiramate may be of particular interest, as preclinical studies of withdrawal from opioids suggest that whilst AMPA-receptor antagonists may not be able to prevent tolerance or dependence from developing, they may ameliorate both physical and emotional consequences of withdrawal. Methods. Ten consecutively admitted patients treated with topiramate were compared in a retrospective naturalistic drug utilization observation study with 10 consecutively admitted patients treated with clonidine and with 10 consecutively admitted patients treated with a carbamazepine/ mianserin combination. Results. In 9 cases of the clonidine group and in 7 carbamazepine/mianserin treated patients the dose had been reduced, whereas this occurred in only 2 topiramate treated patients (p < 0.01). Patients in the topiramate group received less p.r.n. myorelaxant medication than the two other groups, and there was a significant difference between the three groups with regard to p.r.n. analgesics (p < 0.05), topiramate and clonidine treated patients receiving fewer analgesics than the carbamazepine/mianserin group. Conclusions. Compared to clonidine and carbamazepine/mianserin, a detoxification scheme using high initial and then decreasing doses of topiramate appeared to be appropriate for most patients and as associated with less analgesic and myorelaxant comedication, indicating a more promising efficacy at the used doses
Pubmed
Création de la notice
10/03/2008 15:34
Dernière modification de la notice
03/03/2018 22:40
Données d'usage